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c e L L  T Y P e /
O R G A n
P R O T e I n L O s s  O f  f U n c T I O n  P H e n O T Y P e s
systemic IR Apparently normal intrauterine growth and development, severe hyperglycemia and hyperke-
tonemia, perinatal death as the result of diabetic ketoacidosis within 48–72 hours
IRS-1 Retarded embryonal and postnatal growth, insulin resistance, normal fasting glycemia and 
normal or mild glucose intolerance, hyperinsulinemia
IRS-2 Insulin resistance, impaired glucose tolerance, impaired insulin secretion, decreased β cell 
mass
Brain IR Obesity, increased body fat mass, insulin resistance, hyperinsulinemia, hypertriglyceridemia, 
increased food intake (female only)
IRS-2 Obesity, increased body fat mass, insulin resistance, impaired glucose tolerance, 
hyperinsulinemia, extended life span, more active and greater glucose oxidation, increased 
superoxide dismutase-2 in the hypothalamus
Liver IR Normal body weight, severe insulin resistance, impaired glucose tolerance, hyperinsulinemia, 
increased hepatic glucose production
IRS-1 Normal body weight, normal insulin sensitivity during fasting but insulin resistance after 
refeeding
IRS-2 Normal body weight, normal insulin sensitivity after refeeding but insulin resistance during fast-
ing
IRS-1/IRS-2 Normal body weight, severe insulin resistance, severe glucose intolerance, marked hyperin-
sulinemia
skeletal muscle IR Normal body weight, normal insulin and glucose tolerance, increased epididymal fat pad, 
hypertriglyceridemia, increased FFA levels
IRS-1 Normal body weight, normal insulin and glucose tolerance, decreased skeletal muscle mass
IRS-2 Normal body weight, normal insulin and glucose tolerance, normal skeletal muscle mass
IRS-1/IRS-2 Reduced body weight and body length, insulin resistance, normal glucose tolerance, reduced 
skeletal muscle mass, increased lactate levels
Heart IR Normal body weight, normal insulin and glucose tolerance, decreased cardiac size and cardiac 
output, decreased fatty acid oxidation 
Kidney IR Normal body weight, normal insulin and glucose tolerance, albuminuria, histological features of 
diabetic nephropathy
β cell IR Normal body weight, normal insulin tolerance, impaired glucose tolerance, impaired glucose-
stimulated insulin secretion, decreased β cell mass
IRS-2 Impaired glucose tolerance, impaired insulin secretion, decreased β cell mass
Macrophage IR Normal body weight, normal insulin and glucose tolerance, protected from obesity-linked insulin 
resistance due to decreased hepatic glucose production and increased glucose disposal in 
skeletal muscle
endothelial cell IR Normal body weight, normal insulin and glucose tolerance, reduced eNOS and endothelin-1 
expression, insulin resistance on a low-salt diet
IRS-1 Normal body weight, normal insulin and glucose tolerance, normal insulin signaling in 
endothelial cells
IRS-2 Normal body weight, insulin resistance, impaired glucose tolerance, impaired insulin-induced 
eNOS phosphorylation, attenuation of insulin-induced capillary recruitment and insulin 
delivery associated with reduced glucose uptake by skeletal muscle
IRS-1/IRS-2 Normal body weight, insulin resistance, impaired glucose tolerance, impaired insulin-induced 
eNOS phosphorylation in endothelial cells
Adipose tissue IR Reduced body weight and fat mass, protected from Gold thioglucose (GTG)-induced obesity, 
insulin resistance, impared glucose tolerance, extended life span
systemic IR mutation
Hyperglycemia, hyperinsulinemia, severe insulin resistance, acanthosis nigricans, hyperandro-
genemia
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Many facets of metabolic syndrome arise from changes in insulin sensitivity and the downstream signaling responses. Mouse models have provided useful tools for studying and 
understanding the mechanisms underlying the human disease phenotypes. Insulin signaling relies on activation of the insulin receptor (IR) and subsequent phosphorylation of 
insulin receptor substrates (IRS), particularly IRS-1 and IRS-2. This SnapShot provides a guide to the mouse phenotypes resulting from knockout of IR, IRS-1, IRS-2, or IRS-1 and 
IRS-2 in different tissues and cell types. These phenotypes illustrate that IRS-1 and IRS-2 only show partial functional overlap. The systemic consequences of human mutations 
in IR are included and show highly related phenotypic outcomes.
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